review_heavy
Review literature is very dense relative to primary central evidence.
fulltoplow inflation risk
Fusobacterium nucleatum
colorectal cancer
Fusobacterium nucleatum looks like a credible signal in colorectal cancer, though some caution is still warranted.
Fusobacterium nucleatum shows a strong literature footprint in colorectal cancer, with substantial central evidence and broader supporting literature.
fusobacterium_nucleatum
Credibility score
72
Human translation
3/5
Reproducibility
5/5
Novelty
1/5
Actionability
5/5
Credibility 72Human translation 3/5Reproducibility 5/5Novelty 1/5Actionability 5/5
Why this scores the way it does
- strong central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- directionality and confounding still require curated review
Internal review flags
2 flagssparse_primary_supporting_bucket
Central evidence is high but primary supporting bucket is empty. Classification tiers may still be too coarse.
Primary central evidence
20 papersFusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin.
2013Cell host & microbe
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
2016Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer.
2017Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy.
2017Cell
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The oral microbiota in colorectal cancer is distinctive and predictive.
2018Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.
2017Science (New York, N.Y.)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer.
2019Nature medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7.
2020Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization.
2021Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis.
2022Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis.
2022Nature communications
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer.
2023Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer.
2022Nature
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche.
2024Nature
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway.
2024Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
An Empirical Dietary Pattern Associated With the Gut Microbial Features in Relation to Colorectal Cancer Risk.
2024Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer.
2024Cancer cell
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Multi-cohort analysis reveals colorectal cancer tumor location-associated fecal microbiota and their clinical impact.
2025Cell host & microbe
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
An interplay between human genetics and intratumoral microbiota in the progression of colorectal cancer.
2025Cell host & microbe
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Personalized colorectal cancer risk assessment through explainable AI and Gut microbiome profiling.
2025Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
13 papersFusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.
2013Cell host & microbe
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc.
2016Cell host & microbe
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1.
2019EMBO reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression.
2020Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fusobacterium nucleatum Secretes Outer Membrane Vesicles and Promotes Intestinal Inflammation.
2021mBio
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.
2021Signal transduction and targeted therapy
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The gut microbial metabolite formate exacerbates colorectal cancer progression.
2022Nature metabolism
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer.
2023Cell host & microbe
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Consistent signatures in the human gut microbiome of old- and young-onset colorectal cancer.
2024Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The adhesin RadD enhances Fusobacterium nucleatum tumour colonization and colorectal carcinogenesis.
2024Nature microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fusobacterium nucleatum extracellular vesicles are enriched in colorectal cancer and facilitate bacterial adhesion.
2024Science advances
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fusobacterium nucleatum promotes colorectal cancer through neogenesis of tumor stem cells.
2025The Journal of clinical investigation
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest.
2026Cancer cell
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
21 papersFusobacterium nucleatum: a commensal-turned pathogen.
2015Current opinion in microbiology
Relevant review or meta-analysis for the signal-disease area.
Food, microbiome and colorectal cancer.
2018Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Relevant review or meta-analysis for the signal-disease area.
Fusobacterium nucleatum - symbiont, opportunist and oncobacterium.
2019Nature reviews. Microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications.
2019Nature reviews. Gastroenterology & hepatology
Relevant review or meta-analysis for the signal-disease area.
The Intestinal Microbiota and Colorectal Cancer.
2020Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Colorectal cancer: the facts in the case of the microbiota.
2022The Journal of clinical investigation
Relevant review or meta-analysis for the signal-disease area.
Meta-Analysis of Altered Gut Microbiota Reveals Microbial and Metabolic Biomarkers for Colorectal Cancer.
2022Microbiology spectrum
Relevant review or meta-analysis for the signal-disease area.
Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer.
2023Trends in microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota, inflammatory bowel disease and colorectal cancer.
2022World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
The Oral-Gut Axis: Periodontal Diseases and Gastrointestinal Disorders.
2023Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Intestinal bacteria and colorectal cancer: etiology and treatment.
2023Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer.
2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Relevant review or meta-analysis for the signal-disease area.
Colorectal cancer and gut microbiota studies in China.
2023Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Phage therapy in gut microbiome.
2023Progress in molecular biology and translational science
Relevant review or meta-analysis for the signal-disease area.
Biomarkers in Colorectal Cancer: Actual and Future Perspectives.
2024International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Intratumoral Fusobacterium nucleatum in Pancreatic Cancer: Current and Future Perspectives.
2024Pathogens (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
The Oral Microbiome and Cancer.
2025Advances in experimental medicine and biology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection.
2025International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Intestinal dysbiosis and colorectal cancer.
2025Chinese medical journal
Relevant review or meta-analysis for the signal-disease area.
Fusobacterium nucleatum: ecology, pathogenesis and clinical implications.
2026Nature reviews. Microbiology
Relevant review or meta-analysis for the signal-disease area.
Microbe-driven immune suppression in colorectal cancer: the Fusobacterium nucleatum playbook.
2026Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.